Pegvisomant
- Generic Name
- Pegvisomant
- Brand Names
- Somavert
- Drug Type
- Biotech
- CAS Number
- 218620-50-9
- Unique Ingredient Identifier
- N824AOU5XV
- Background
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
- Indication
Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
- Associated Conditions
- Acromegaly
Acute Application of Pegvisomant and Octreotide in Acromegaly
- Conditions
- Acromegaly
- Interventions
- Drug: combination with somatostatin analogue octreotideDrug: combination with dopamine agonist cabergoline
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 10
- Registration Number
- NCT00595140
- Locations
- 🇩🇪
Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany
Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- University of Wuerzburg
- Target Recruit Count
- 4
- Registration Number
- NCT00552851
- Locations
- 🇩🇪
University of Wuerzburg, Department of Endocrinology, Wuerzburg, Bavaria, Germany
Growth Hormone Signaling in Vivo in Humans
- Conditions
- Intracellular Signaling Peptides and Proteins
- Interventions
- First Posted Date
- 2007-08-07
- Last Posted Date
- 2007-08-07
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 8
- Registration Number
- NCT00512473
- Locations
- 🇩🇰
Medical Research Laboratories, Aarhus, Denmark
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 125
- Registration Number
- NCT00383708
- Locations
- 🇩🇪
Charite Campus Mitte, Berlin, Germany
🇫🇷CHU de Rangueil, Toulouse, France
🇮🇹University Federico II, Napoli, Italy
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
- Conditions
- Acromegaly
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00151437
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Long Term Study With B2036-PEG
- Conditions
- Acromegaly
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00143416
- Locations
- 🇯🇵
Pfizer Investigational Site, Sannomaru-cho, Naka-ku, Nagoya-shi, Japan
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2003-09-08
- Last Posted Date
- 2008-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00068042
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Pegvisomant And Sandostatin LAR Combination Study
- Conditions
- Acromegaly
- First Posted Date
- 2003-09-05
- Last Posted Date
- 2008-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT00068029
- Locations
- 🇬🇧
Pfizer Investigational Site, Oxford, United Kingdom
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
- Conditions
- McCune Albright SyndromePolyostotic Fibrous Dysplasia
- First Posted Date
- 2001-06-21
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- Target Recruit Count
- 10
- Registration Number
- NCT00017927
- Locations
- 🇺🇸
National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.